Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04828161 · ClinicalTrials.gov registry record · Phase 2
A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 407
- Enrollment target
NCT04828161 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 407 participants.
The verdict
NCT04828161, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 407 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for treating COVID-19 in adult ambulatory patients.
Interventions
- DRUG Placebo
- DRUG ensovibep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 407 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2022-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04828161
The ClinicalTrials.gov registry entry for NCT04828161 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04828161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04828161 about?
NCT04828161 is a clinical study titled "A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19". The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for treating COVID-19 in adult ambulatory patients.
What is the current status of trial NCT04828161?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 407 participants. The study started on 2021-05-10. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT04828161?
The interventions under investigation include: Placebo (DRUG), ensovibep (DRUG).
Who is sponsoring clinical trial NCT04828161?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.